{"id":1585,"date":"2010-09-01T12:00:00","date_gmt":"2010-09-01T10:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/diabetes-mellitus-typ-2-epidemiologie-und-neue-therapiestrategien"},"modified":"2010-09-01T12:00:00","modified_gmt":"2010-09-01T10:00:00","slug":"diabetes-mellitus-typ-2-epidemiologie-und-neue-therapiestrategien","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/diabetes-mellitus-typ-2-epidemiologie-und-neue-therapiestrategien","title":{"rendered":"Diabetes mellitus Typ 2. Epidemiologie und neue Therapiestrategien"},"content":{"rendered":"<p>Die Zeitschrift Lancet widmete im Juni ein ganzes Heft dem Thema Diabetes mellitus Typ 2 (DM2), parallel zur 70. Tagung der American Diabetes Association vom 26.-29. Juni 2010 in Orlando, Florida. In einem einleitenden Editorial (1) wird bedauert, dass in der wissenschaftlichen Diskussion dieser und anderer aktueller Kongresse die Bedeutung und praktische Durchsetzbarkeit von \u00c4nderungen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die Zeitschrift Lancet widmete im Juni ein ganzes Heft dem Thema Diabetes mellitus Typ 2 (DM2), parallel zur 70. Tagung der American Diabetes Association vom 26.-29. Juni 2010 in Orlando, Florida. In einem einleitenden Editorial (1) wird bedauert, dass in der wissenschaftlichen Diskussion dieser und anderer aktueller Kongresse die Bedeutung und praktische Durchsetzbarkeit von \u00c4nderungen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[60,324,1556,48,155,3705,2822,1558,71,68,325,50,498,65,1557,56,1552,1550,1551,3703,3704],"class_list":["post-1585","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-apoplektischer-insult","tag-blutdruck","tag-dapagliflozin","tag-diabetes-mellitus","tag-diabetes-mellitus-typ-2","tag-duration-3-studie","tag-exenatid","tag-gliflozine","tag-herzinfarkt","tag-hirninfarkt","tag-hypertonie","tag-insulin","tag-koronare-herzkrankheit","tag-myokardinfarkt","tag-natrium-glukose-cotransporter-2","tag-schlaganfall","tag-sglt2","tag-sglt2-hemmer","tag-sglt2-inhibitoren","tag-t-i","tag-technosphere-inhaled-insulin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1585"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1585\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}